# ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

> **NCT05081245** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MapLight Therapeutics** · enrollment: 150 (estimated)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** ML-004 (IR)/(ER) tablet
- **DRUG:** ML-004 Placebo

## Key facts

- **NCT ID:** NCT05081245
- **Lead sponsor:** MapLight Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081245, "ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05081245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*